TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Percent Time in Remission (PTIR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence or absence of fracture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Psychological trauma symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Advancement of tractional detachment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Change in glycosylated hemoglobin (HbA1c) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in sodium excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sensory Gating Inventory score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Highest amount of grams of sugar in solutions without significant increase in IBS symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: All cause follow up
Endpoint domain: Mortality/survival
Primary endpoint: Changes in HRV recording parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in 28 Day Partial Seizure Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cerebral metabolic rate of oxygen index (CMRO2i)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Plasma Concentration (Cmax) of ZL-2102
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUC) of ZL-2102
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient-reported Pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patient-reported Anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patient-reported Overall Experience
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Postoperative bleeding (mL blood in the chest tubes)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of a major cardiovascular event or complication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: OGTT result
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area Under the Serum Concentration Curve (AUC72h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: P50 Auditory Evoked Potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Provider Use of PE Components
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: PCr recovery after submaximal exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative Morphine Equivalent Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC (0-t): Area Under the Concentration-Time Curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Serious Adverse Events (SAEs) and Non-Serious Adverse Events (Non-SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Scaling size decrement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histopathological improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of new onset of confirmed autoimmune disease for neuroinflammatory/ophthalmic autoimmune diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Occurrence of new onset of confirmed autoimmune disease for other autoimmune diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Level of unconjugated hyperbilirubinemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change on HVLT-R delayed recall
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cervical Functional Limitations
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Residualized Change in Counts of Unprotected Anal Intercourse at 3 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Residualized Change in Counts of Unprotected Anal Intercourse at 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attack rate after challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mean Change From Baseline in Subject-rated Reflective TNSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Repeat pregnancy
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Parenting attitudes and behaviors
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: School continuation or graduation
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Degree of concordance between diagnoses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptance and practicality of the FDDT
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Serum ALT normalization rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression of EBV lytic cycle antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: number of implantable cardioverter defibrillator shocks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: tumor recurrence and metastasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Rate of first cardiovascular disorder events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 6 month IUD usage rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence and severity of brain injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence and severity of white matter injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Area Under the Concentration-time Curve in One Dosing Interval [AUC(TAU)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived Stigma and Barriers to Care for Psychological Problems
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Readiness to Change
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Self-Stigma of Seeking Help
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: COVID-19-related anxiety symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: treatment-related symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incisional hernia rate
Endpoint domain: Adverse events/effects
Primary endpoint: Relative bioavailability of inhaled Staccato apomorphine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose Proportionality by Power Analysis of AUCinf
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Postural Stability performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Chair Stand performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sudden Cardiac Arrest Events
Endpoint domain: Mortality/survival
Primary endpoint: Percent Change in Partial Seizure Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percent change in brain amyloid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percent change in cortical ribbon thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Responder of Complete Spontaneous Bowel Movement (CSBM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: systemic reactions > grade I or large local reactions
Endpoint domain: Adverse events/effects
Primary endpoint: percentage of positive QFT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: percentage of positive QFT change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: number of scans ordered subject to CDS best practice alert
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change From Baseline in Clinical Disease Activity Index (CDAI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first documented relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Precision at the contralateral arms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal oxygen uptake (VO2peak)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Average Hourly FEV1 AUC0-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Hippocampal subfield gray matter density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Area under the curve (AUC) of the log10 Nasal Viral Load on Day 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Area Under the Concentration-time Curve From Time Zero to the Time of the Last Measurable Concentration (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of Sedation Based on Average Ramsay Sedation Scale (RSS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects Who Received Rescue Medication for Sedation (Midazolam) and Analgesics (Fentanyl)
Endpoint domain: Adverse events/effects
Primary endpoint: Quality of Sedation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean Percent Change in Gait Speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Received Preparative Chemotherapy Followed by CD19 CAR T-cells With < Grade 4 Cytokine Release Syndrome
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants in Which the Prescribed Dose of CD19 CAR T-cells Were Successfully Manufactured
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Participants' awareness of PAD
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: helpline utilization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in maximal time in the upright position without support
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perfusion-oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Upper Limb Muscle Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Net therapeutic benefit of enoxaparin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma oxidized low-density lipoprotein levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to reach a PRAM score of ≤3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: iron excretion in urine and stool
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: pharmacokinetic measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Carbohydrate/fat oxidation (RER) in the fasting condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Muscle oxygen consumption (substrate oxidation) in the fasting condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Muscle lactate release in the fasting condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in swallowing disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fascial dehiscence incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Bone Augmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: 3 D acceleration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amiodarone concentration in fat tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulated dose of Amiodarone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Developing adverse effects
Endpoint domain: Adverse events/effects
Primary endpoint: RNA viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-reported adherence (CASE index)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: health-related quality of life (EQ-5D/EQ-VAS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Area under the ROC curve of neutrophil myeloperoxidase expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ALT change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Severity of keratitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: one week reattachment rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Bacterial flora of the respiratory tract
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rate of any major adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Glutathione
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Readers' Level of Confidence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from baseline cry duration in seconds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Body Fat Percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality after cardiac surgery
Endpoint domain: Mortality/survival
Primary endpoint: Drug-related problems
Endpoint domain: Adverse events/effects
Primary endpoint: Alveolar Bone Dimensional Reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Flexion rotation test (FRT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neck disability index (NDI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Blood flow spectrum of the radial artery and dorsal artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Tissue oxygen of the compartment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to Transformation to AML
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of biomarker panel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Affiliated risk score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge retention scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: duration of spontaneous ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Repeatability of NaF PET/CT imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of participants with worsening of dyspnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of participants with respiratory functional worsening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percent change in mean number of urgency episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contractile activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cellular immunity to varicella zoster
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Image visibility of enhancing finding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiovascular data
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: % treated wound excised (by tangential/minor/Versajet excision) or dermabrasion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: % treated wound autografted
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Radiation dermatitis severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Geometric Mean Titers (GMTs) to Each of the HPV Types Contained in the Vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants Who Seroconverted to Each of the HPV Types Contained in the Vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from preclinical phase of AD to Mild Cognitive Impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Component alignment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in Inferior Corneal Fluorescein Staining Score to Day 84
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Eye Dryness Score (Visual Analogue Scale) to Day 84
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breast Projection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: digestive tolerability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Total Body Dual-Emission X-ray Absorptiometry (DEXA) Scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Lower and upper extremity strength testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Scoring >3
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of Recruitment of Eligible Participants
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of Participants That Completed Questionnaires
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Nasopharyngeal colonization by streptococcus pneumoniae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in Modified Baron Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3-Dimensional Scapular Kinematics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Orexin Levels (Blood)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Accuracy of Enlite sensor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anti-Protein D (PD) Antibody Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-Protein E (PE) Antibody Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-type IV Pili Subunit (PilA) Antibody Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-ubiquitous Surface Protein A2 of Moraxella Catarrhalis (UspA2) Antibody Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Lead-time of sevoflurane sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Marital and sexual satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Decompensated rate of Liver Cirrhosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Prevention of atrial fibrillation recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Quantitation of gut tissue IL-5+ and IL-5- Th2 cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Quantitation of gut tissue Th2 cells using alternative techniques
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Quantitation of gut tissue IFN-, IL-17 and IL-10 producing cell populations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline to End of Treatment in Post Void Residual (PVR) Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change From Baseline to End of Treatment in Maximum Flow Rate (Qmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change From Baseline to End of Treatment in Average Flow Rate (Qmean)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes